iBio Appoints Biotech Veteran Dr. Elizabeth Stoner to Board, Strengthening Clinical Development Expertise

summarizeSummary

iBio appointed Dr. Elizabeth Stoner, a distinguished biotech leader with extensive R&D and clinical development experience, to its Board of Directors, while Evert Schimmelpennink resigned without disagreement.

check_boxKey Events

• New Director Appointed

  Dr. Elizabeth Stoner, M.D., M.S., was appointed as a Class II director to iBio's Board, effective May 7, 2026. She will also serve as a member of the Compensation Committee.

• Enhanced Clinical and R&D Expertise

  Dr. Stoner brings over 35 years of experience, including leadership roles at MPM BioImpact, Merck Research Laboratories, and Rhythm Pharmaceuticals, which is highly valuable as iBio transitions to a clinical-stage company.

• Director Resignation

  Evert Schimmelpennink resigned from the Board and Compensation Committee, effective May 7, 2026. The company stated his resignation was not due to any disagreements and his position was immediately filled by Dr. Stoner.

auto_awesomeAnalysis

iBio, a clinical-stage biotech company, has appointed Dr. Elizabeth Stoner to its Board of Directors, a move that significantly enhances the board's expertise in research, development, and clinical strategy. Dr. Stoner brings over 35 years of experience, including leadership roles at MPM BioImpact, Merck Research Laboratories, and as a founder of Rhythm Pharmaceuticals. Her background is particularly relevant as iBio prepares to initiate its first human clinical trials for its AI-driven therapies. Concurrently, Evert Schimmelpennink resigned from the board, though the company stated his departure was not due to any disagreements, and his vacancy was immediately filled by Dr. Stoner. This strategic appointment is a positive development, providing critical guidance as iBio advances its pipeline.